Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2013

01.06.2013 | Epidemiology

Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands

verfasst von: A. Font-Gonzalez, L. Liu, A. C. Voogd, M. K. Schmidt, J. A. Roukema, J. W. W. Coebergh, E. de Vries, I. Soerjomataram

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

To compare overall survival between women with unilateral breast cancer (UBC) and contralateral breast cancer (CBC). Women with UBC (N = 182,562; 95 %) and CBC (N = 8,912; 5 %) recorded in the Netherlands Cancer Registry between 1989 and 2008 were included and followed until 2010. We incorporated CBC as a time-dependent covariate to compute the overall mortality rate ratio between women with CBC and UBC. Prognostic factors for overall death were examined according to age at first breast cancer. Women with CBC exhibited a 30 % increase in overall mortality (Hazard Ratio (HR), 95 % Confidence Interval: 1.3, 1.3–1.4) compared with UBC, decreasing with rising age at diagnosis of first breast cancer (<50 years: 2.3, 2.2–2.5 vs. ≥70 years: 1.1, 1.0–1.1). Women older than 50 years at CBC diagnosis and diagnosed 2–5 years after their first breast cancer exhibited a 20 % higher death risk (1.2, 1.0–1.3) compared to those diagnosed within the first 2 years. In women younger than 50 years, the HR was significantly lower if the CBC was diagnosed >5 years after the first breast cancer (0.7, 0.5–0.9). The prognosis for women with CBC significantly improved over time (2004–2008: 0.6, 0.5-0.7 vs. 1989–1993). Women with CBC had a lower survival compared to women with UBC, especially those younger than 50 years at first breast cancer diagnosis. A tailored follow-up strategy beyond current recommendations is needed for these patients who, because of their age and absence of known familial risk, are currently not invited for population-based screening.
Literatur
1.
Zurück zum Zitat Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380:1840–1850. doi:10.1016/S0140-6736(12)60919-2 Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380:1840–1850. doi:10.​1016/​S0140-6736(12)60919-2
3.
Zurück zum Zitat Louwman WJ, Voogd AC, van Dijck J, Nieuwenhuijzen GA, Ribot J, Pruijt JF, Coebergh JW (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19:97–106PubMedCrossRef Louwman WJ, Voogd AC, van Dijck J, Nieuwenhuijzen GA, Ribot J, Pruijt JF, Coebergh JW (2008) On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 19:97–106PubMedCrossRef
4.
Zurück zum Zitat Karim-Kos HE, Kiemeney LALM, Louwman MWJ, Coebergh JWW, de Vries E (2012) Progress against cancer in the Netherlands since the late 1980s: an epidemiological evaluation. Int J Cancer 130:2981–2989PubMedCrossRef Karim-Kos HE, Kiemeney LALM, Louwman MWJ, Coebergh JWW, de Vries E (2012) Progress against cancer in the Netherlands since the late 1980s: an epidemiological evaluation. Int J Cancer 130:2981–2989PubMedCrossRef
5.
Zurück zum Zitat Nationwide breast cancer screening programme fully implemented in the Netherlands, Fracheboud J, de Koning HJ, Boer R, Groenewoud JH, Verbeek ALM, Broeders MJM, van Ineveld BM, Hendriks JHCL, de Bruyn AE, Holland R, van der Maas PJ (2001) Nationwide breast cancer screening programme fully implemented in the Netherlands. Breast 10:6–11PubMedCrossRef Nationwide breast cancer screening programme fully implemented in the Netherlands, Fracheboud J, de Koning HJ, Boer R, Groenewoud JH, Verbeek ALM, Broeders MJM, van Ineveld BM, Hendriks JHCL, de Bruyn AE, Holland R, van der Maas PJ (2001) Nationwide breast cancer screening programme fully implemented in the Netherlands. Breast 10:6–11PubMedCrossRef
7.
Zurück zum Zitat Soerjomataram I, Louwman WJ, Lemmens VEPP, de Vries E, Klokman WJ, Coebergh JWW (2005) Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972–2001. Eur J Cancer 41:2331–2337PubMedCrossRef Soerjomataram I, Louwman WJ, Lemmens VEPP, de Vries E, Klokman WJ, Coebergh JWW (2005) Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972–2001. Eur J Cancer 41:2331–2337PubMedCrossRef
8.
Zurück zum Zitat Holmberg L, Adami H, Ekbom A, Bergstram R, Sandstram A, Lindgren A (1988) Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. Br J Cancer 58:191–194PubMedCrossRef Holmberg L, Adami H, Ekbom A, Bergstram R, Sandstram A, Lindgren A (1988) Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. Br J Cancer 58:191–194PubMedCrossRef
9.
Zurück zum Zitat Brenner H, Engelsmann B, Stegmaier C, Ziegler H (1993) Clinical epidemiology of bilateral breast cancer. Cancer 72:3629–3635PubMedCrossRef Brenner H, Engelsmann B, Stegmaier C, Ziegler H (1993) Clinical epidemiology of bilateral breast cancer. Cancer 72:3629–3635PubMedCrossRef
10.
Zurück zum Zitat Gajalakshmi C, Shanta V, Hakama M (1999) Survival from contralateral breast cancer. Breast Cancer Res Treat 58:115–122PubMedCrossRef Gajalakshmi C, Shanta V, Hakama M (1999) Survival from contralateral breast cancer. Breast Cancer Res Treat 58:115–122PubMedCrossRef
11.
Zurück zum Zitat Abdalla I, Thisted R, Heimann R (2000) The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J 6:266–272PubMed Abdalla I, Thisted R, Heimann R (2000) The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J 6:266–272PubMed
12.
Zurück zum Zitat Jobsen JJ, Jvd Palen, Ong F, Meerwaldt JH (2003) Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 12:83–88PubMedCrossRef Jobsen JJ, Jvd Palen, Ong F, Meerwaldt JH (2003) Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 12:83–88PubMedCrossRef
13.
Zurück zum Zitat Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210–4216PubMedCrossRef Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210–4216PubMedCrossRef
14.
Zurück zum Zitat Schaapveld M, Visser O, Louwman W, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197PubMedCrossRef Schaapveld M, Visser O, Louwman W, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197PubMedCrossRef
15.
Zurück zum Zitat Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS (2009) Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 100:563–570PubMedCrossRef Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS (2009) Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer 100:563–570PubMedCrossRef
16.
Zurück zum Zitat Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M (2011) Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat 130:609–618PubMedCrossRef Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M (2011) Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat 130:609–618PubMedCrossRef
17.
Zurück zum Zitat Schwentner L, Wolters R, Wischnewsky M, Kreienberg R, Wöckel A (2012) Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast 21:171–177PubMedCrossRef Schwentner L, Wolters R, Wischnewsky M, Kreienberg R, Wöckel A (2012) Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast 21:171–177PubMedCrossRef
18.
Zurück zum Zitat Heron D, Komarnicky L, Hyslop T, Schwartz G, Mansfield C (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88:2739–2750PubMedCrossRef Heron D, Komarnicky L, Hyslop T, Schwartz G, Mansfield C (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88:2739–2750PubMedCrossRef
19.
Zurück zum Zitat Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S (2005) The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer 12:196–202PubMedCrossRef Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S (2005) The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer 12:196–202PubMedCrossRef
20.
Zurück zum Zitat Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357PubMedCrossRef Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357PubMedCrossRef
21.
Zurück zum Zitat Irvine T, Allen DS, Gillett C, Hamed H, Fentiman IS (2009) Prognosis of synchronous bilateral breast cancer. Br J Surg 96:376–380PubMedCrossRef Irvine T, Allen DS, Gillett C, Hamed H, Fentiman IS (2009) Prognosis of synchronous bilateral breast cancer. Br J Surg 96:376–380PubMedCrossRef
22.
Zurück zum Zitat Mose S, Adamietz IA, Thilmann C, Saran F, Bernhard M, Pahnke R, Böttcher HD (1997) Bilateral breast carcinoma versus unilateral disease: review of 498 patients. Am J Clin Oncol 20:541–545PubMedCrossRef Mose S, Adamietz IA, Thilmann C, Saran F, Bernhard M, Pahnke R, Böttcher HD (1997) Bilateral breast carcinoma versus unilateral disease: review of 498 patients. Am J Clin Oncol 20:541–545PubMedCrossRef
23.
Zurück zum Zitat Michowitz M, Noy S, Lazebnik N, Aladjem D (1985) Bilateral breast cancer. J Surg Oncol 30:109–112PubMedCrossRef Michowitz M, Noy S, Lazebnik N, Aladjem D (1985) Bilateral breast cancer. J Surg Oncol 30:109–112PubMedCrossRef
24.
Zurück zum Zitat Gustafsson A, Tartter P, Brower S, Lesnick G (1994) Prognosis of patients with bilateral carcinoma of the breast. J Am Coll Surg 178:111–116PubMed Gustafsson A, Tartter P, Brower S, Lesnick G (1994) Prognosis of patients with bilateral carcinoma of the breast. J Am Coll Surg 178:111–116PubMed
25.
Zurück zum Zitat Skowronek J, Piotrowski T (2002) Bilateral breast cancer. Neoplasma 49:49–54PubMed Skowronek J, Piotrowski T (2002) Bilateral breast cancer. Neoplasma 49:49–54PubMed
26.
Zurück zum Zitat Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMed Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19–24PubMed
27.
Zurück zum Zitat Schouten LJ, Jager JJ, van den Brandt PA (1993) Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer 68:974–977PubMedCrossRef Schouten LJ, Jager JJ, van den Brandt PA (1993) Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer 68:974–977PubMedCrossRef
28.
Zurück zum Zitat Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ (1993) Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22:369–376PubMedCrossRef Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ (1993) Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22:369–376PubMedCrossRef
29.
Zurück zum Zitat International Association of Cancer Registries (IACR) (2005) International rules for multiple primary cancers. Asian Pac J Cancer Prev 6:104–106 International Association of Cancer Registries (IACR) (2005) International rules for multiple primary cancers. Asian Pac J Cancer Prev 6:104–106
30.
Zurück zum Zitat Rothman KJ, Greenland S (1998) Cohort studies. In: Rothman KJ, Greenland S (eds) Modern epidemiology, 2nd edn. Lippincott-Raven, Philadelphia, pp 79–91 Rothman KJ, Greenland S (1998) Cohort studies. In: Rothman KJ, Greenland S (eds) Modern epidemiology, 2nd edn. Lippincott-Raven, Philadelphia, pp 79–91
31.
Zurück zum Zitat Maaskant AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Tutein Nolthenius-Puylaert MC, Nieuwenhuijzen GA (2009) Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res Treat 113:173–179PubMedCrossRef Maaskant AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Tutein Nolthenius-Puylaert MC, Nieuwenhuijzen GA (2009) Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res Treat 113:173–179PubMedCrossRef
32.
Zurück zum Zitat Janssen-Heijnen ML, van Steenbergen LN, Voogd AC, Nijhuis PH, Poortmans PH, Coebergh JW (2012) Long-term excess mortality for survivors of breast cancer in the Netherlands 2013 (submitted) Janssen-Heijnen ML, van Steenbergen LN, Voogd AC, Nijhuis PH, Poortmans PH, Coebergh JW (2012) Long-term excess mortality for survivors of breast cancer in the Netherlands 2013 (submitted)
34.
Zurück zum Zitat Neta G, Anderson WF, Gilbert E, Berrington A (2012) Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER. Breast Cancer Res Treat 131:1021–1027PubMedCrossRef Neta G, Anderson WF, Gilbert E, Berrington A (2012) Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER. Breast Cancer Res Treat 131:1021–1027PubMedCrossRef
35.
Zurück zum Zitat Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065PubMedCrossRef Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065PubMedCrossRef
36.
Zurück zum Zitat Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P (2005) Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 6:377–382PubMedCrossRef Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P (2005) Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 6:377–382PubMedCrossRef
38.
Zurück zum Zitat Vichapat V, Garmo H, Holmqvist M, Liljegren G, Wärnberg F, Lambe M, Fornander T, Adolfsson J, Lüchtenborg M, Holmberg L (2012) Tumour stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol 30:3478–3484PubMedCrossRef Vichapat V, Garmo H, Holmqvist M, Liljegren G, Wärnberg F, Lambe M, Fornander T, Adolfsson J, Lüchtenborg M, Holmberg L (2012) Tumour stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol 30:3478–3484PubMedCrossRef
39.
Zurück zum Zitat Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, Hayward JL (1984) Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 71:711–714PubMedCrossRef Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, Hayward JL (1984) Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 71:711–714PubMedCrossRef
40.
Zurück zum Zitat Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R (2001) Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 67:1–8PubMedCrossRef Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R (2001) Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 67:1–8PubMedCrossRef
41.
Zurück zum Zitat Brommesson S, Jönsson G, Strand C, Grabau D, Malmström P, Ringnér M, Fernö M, Hedenfalk I (2008) Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC Clin Pathol 8:6PubMedCrossRef Brommesson S, Jönsson G, Strand C, Grabau D, Malmström P, Ringnér M, Fernö M, Hedenfalk I (2008) Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC Clin Pathol 8:6PubMedCrossRef
42.
Zurück zum Zitat Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M (2012) Patterns of metastasis in women with metachronous contralateral breast cancer. Br J Cancer 107:221–223PubMedCrossRef Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Lüchtenborg M (2012) Patterns of metastasis in women with metachronous contralateral breast cancer. Br J Cancer 107:221–223PubMedCrossRef
45.
Zurück zum Zitat Houssami N, Abraham LA, Miglioretti DL, Sickles EA, Kerlikowske K, Buist DS, Geller BM, Muss HB, Irwig L (2011) Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 305:790–799PubMedCrossRef Houssami N, Abraham LA, Miglioretti DL, Sickles EA, Kerlikowske K, Buist DS, Geller BM, Muss HB, Irwig L (2011) Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 305:790–799PubMedCrossRef
46.
Zurück zum Zitat Setz-Pels W, Duijm LE, Groenewoud JH, Voogd AC, Jansen FH, Hooijen MJ, Louwman MW (2011) Detection of bilateral breast cancer at biennial screening mammography in the Netherlands: a population-based study. Radiology 260:357–363PubMedCrossRef Setz-Pels W, Duijm LE, Groenewoud JH, Voogd AC, Jansen FH, Hooijen MJ, Louwman MW (2011) Detection of bilateral breast cancer at biennial screening mammography in the Netherlands: a population-based study. Radiology 260:357–363PubMedCrossRef
47.
Zurück zum Zitat Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP III, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G (2012) Detection of breast cancer with addition of annual screening utrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404PubMedCrossRef Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP III, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G (2012) Detection of breast cancer with addition of annual screening utrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404PubMedCrossRef
48.
Zurück zum Zitat Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C (2009) Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy. Hered Cancer Clin Pract 7:6PubMedCrossRef Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C (2009) Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy. Hered Cancer Clin Pract 7:6PubMedCrossRef
49.
Zurück zum Zitat van Schoor G, Broeders MJM, Paap E, Otten JDM, den Heeten GJ, Verbeek ALM (2008) A rational for starting breast cancer screening under age 50. Ann Oncol 19:1208–1209PubMedCrossRef van Schoor G, Broeders MJM, Paap E, Otten JDM, den Heeten GJ, Verbeek ALM (2008) A rational for starting breast cancer screening under age 50. Ann Oncol 19:1208–1209PubMedCrossRef
50.
Zurück zum Zitat Soerjomataram I, Pukkala E, Brenner H, Coebergh JW (2008) On the avoidability of breast cancer in industrialized societies: older mean age at first birth as an indicator of excess breast cancer risk. Breast Cancer Res Treat 111:297–302PubMedCrossRef Soerjomataram I, Pukkala E, Brenner H, Coebergh JW (2008) On the avoidability of breast cancer in industrialized societies: older mean age at first birth as an indicator of excess breast cancer risk. Breast Cancer Res Treat 111:297–302PubMedCrossRef
51.
Zurück zum Zitat Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRef Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen GA, Coebergh JW (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRef
Metadaten
Titel
Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands
verfasst von
A. Font-Gonzalez
L. Liu
A. C. Voogd
M. K. Schmidt
J. A. Roukema
J. W. W. Coebergh
E. de Vries
I. Soerjomataram
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2588-9

Weitere Artikel der Ausgabe 3/2013

Breast Cancer Research and Treatment 3/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.